paclitaxel has been researched along with Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reilich, P; Schessl, J; Schlotter-Weigel, B; Schneiderat, P; Schoser, B; Schuberth, M; Strigl-Pill, N; Walter, MC | 1 |
| Aparicio, LM; Ayerbes, MV; Budino, BS; Campelo, RG; Curbera, GA; Facal, MS; Lopez, MR; Martinez, LC; Novoa, SA; Sancho, MI; Varela, MQ | 1 |
2 other study(ies) available for paclitaxel and Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration
| Article | Year |
|---|---|
Long-term efficiency of intravenously administered immunoglobulin in anti-Yo syndrome with paraneoplastic cerebellar degeneration.
Topics: Aged; Antineoplastic Agents; Carboplatin; Female; Humans; Immunoglobulins, Intravenous; Ovarian Neoplasms; Paclitaxel; Paraneoplastic Cerebellar Degeneration; Polyneuropathies | 2011 |
Subacute cerebellar degeneration as paraneoplastic syndrome: initial symptom of breast cancer with HER2 overexpression.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Diagnosis, Differential; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Paraneoplastic Cerebellar Degeneration; Positron-Emission Tomography; Postmenopause; Receptor, ErbB-2; Risk Assessment; Trastuzumab | 2006 |